744 related articles for article (PubMed ID: 34218353)
21. Revolutionizing cancer treatment: enhancing CAR-T cell therapy with CRISPR/Cas9 gene editing technology.
Tao R; Han X; Bai X; Yu J; Ma Y; Chen W; Zhang D; Li Z
Front Immunol; 2024; 15():1354825. PubMed ID: 38449862
[TBL] [Abstract][Full Text] [Related]
22. Engineering the next-generation of CAR T-cells with CRISPR-Cas9 gene editing.
Dimitri A; Herbst F; Fraietta JA
Mol Cancer; 2022 Mar; 21(1):78. PubMed ID: 35303871
[TBL] [Abstract][Full Text] [Related]
23. Applications and advances of CRISPR-Cas9 in cancer immunotherapy.
Xia AL; He QF; Wang JC; Zhu J; Sha YQ; Sun B; Lu XJ
J Med Genet; 2019 Jan; 56(1):4-9. PubMed ID: 29970486
[TBL] [Abstract][Full Text] [Related]
24. The application of CRISPR-Cas9 genome editing tool in cancer immunotherapy.
Wu HY; Cao CY
Brief Funct Genomics; 2019 Mar; 18(2):129-132. PubMed ID: 29579146
[TBL] [Abstract][Full Text] [Related]
25. CRISPR/Cas9-mediated TGFβRII disruption enhances anti-tumor efficacy of human chimeric antigen receptor T cells in vitro.
Alishah K; Birtel M; Masoumi E; Jafarzadeh L; Mirzaee HR; Hadjati J; Voss RH; Diken M; Asad S
J Transl Med; 2021 Nov; 19(1):482. PubMed ID: 34838059
[TBL] [Abstract][Full Text] [Related]
26. Advancing chimeric antigen receptor T cell therapy with CRISPR/Cas9.
Ren J; Zhao Y
Protein Cell; 2017 Sep; 8(9):634-643. PubMed ID: 28434148
[TBL] [Abstract][Full Text] [Related]
27. CRISPR/Cas9 genome editing: Fueling the revolution in cancer immunotherapy.
Liu X; Zhao Y
Curr Res Transl Med; 2018 May; 66(2):39-42. PubMed ID: 29691200
[TBL] [Abstract][Full Text] [Related]
28. Granulocyte-macrophage colony-stimulating factor inactivation in CAR T-cells prevents monocyte-dependent release of key cytokine release syndrome mediators.
Sachdeva M; Duchateau P; Depil S; Poirot L; Valton J
J Biol Chem; 2019 Apr; 294(14):5430-5437. PubMed ID: 30804212
[TBL] [Abstract][Full Text] [Related]
29. Immune effector cell associated neurotoxicity syndrome in chimeric antigen receptor-T cell therapy.
Sterner RC; Sterner RM
Front Immunol; 2022; 13():879608. PubMed ID: 36081506
[TBL] [Abstract][Full Text] [Related]
30. Therapeutic potential of CRISPR/Cas9 gene editing in engineered T-cell therapy.
Gao Q; Dong X; Xu Q; Zhu L; Wang F; Hou Y; Chao CC
Cancer Med; 2019 Aug; 8(9):4254-4264. PubMed ID: 31199589
[TBL] [Abstract][Full Text] [Related]
31. CAR T-Cell Therapy in Hematological Malignancies.
Haslauer T; Greil R; Zaborsky N; Geisberger R
Int J Mol Sci; 2021 Aug; 22(16):. PubMed ID: 34445701
[TBL] [Abstract][Full Text] [Related]
32. Application of Chimeric Antigen Receptor T Cells in the Treatment of Hematological Malignancies.
Yan W; Liu Z; Liu J; Xia Y; Hu K; Yu J
Biomed Res Int; 2020; 2020():4241864. PubMed ID: 33062678
[TBL] [Abstract][Full Text] [Related]
33. Therapeutic gene editing in haematological disorders with CRISPR/Cas9.
Jensen TI; Axelgaard E; Bak RO
Br J Haematol; 2019 Jun; 185(5):821-835. PubMed ID: 30864164
[TBL] [Abstract][Full Text] [Related]
34. Thrombotic Events Are Unusual Toxicities of Chimeric Antigen Receptor T-Cell Therapies.
Schorr C; Forindez J; Espinoza-Gutarra M; Mehta R; Grover N; Perna F
Int J Mol Sci; 2023 May; 24(9):. PubMed ID: 37176053
[TBL] [Abstract][Full Text] [Related]
35. New targets for CAR T therapy in hematologic malignancies.
Savani M; Oluwole O; Dholaria B
Best Pract Res Clin Haematol; 2021 Sep; 34(3):101277. PubMed ID: 34625226
[TBL] [Abstract][Full Text] [Related]
36. Nucleofection with Plasmid DNA for CRISPR/Cas9-Mediated Inactivation of Programmed Cell Death Protein 1 in CD133-Specific CAR T Cells.
Hu B; Zou Y; Zhang L; Tang J; Niedermann G; Firat E; Huang X; Zhu X
Hum Gene Ther; 2019 Apr; 30(4):446-458. PubMed ID: 29706119
[TBL] [Abstract][Full Text] [Related]
37. Strategies for Reducing Toxicity and Enhancing Efficacy of Chimeric Antigen Receptor T Cell Therapy in Hematological Malignancies.
Wang H; Tang L; Kong Y; Liu W; Zhu X; You Y
Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298069
[TBL] [Abstract][Full Text] [Related]
38. CAR-T cell therapy in hematological malignancies: Where are we now and where are we heading for?
Khan AN; Asija S; Pendhari J; Purwar R
Eur J Haematol; 2024 Jan; 112(1):6-18. PubMed ID: 37545253
[TBL] [Abstract][Full Text] [Related]
39. Chimeric antigen receptor T-cell therapy in hematologic malignancies: Successes, challenges, and opportunities.
Ho M; Zanwar S; Paludo J
Eur J Haematol; 2024 Feb; 112(2):197-210. PubMed ID: 37545132
[TBL] [Abstract][Full Text] [Related]
40. Gene-knocked out chimeric antigen receptor (CAR) T cells: Tuning up for the next generation cancer immunotherapy.
Mirzaei HR; Pourghadamyari H; Rahmati M; Mohammadi A; Nahand JS; Rezaei A; Mirzaei H; Hadjati J
Cancer Lett; 2018 Jun; 423():95-104. PubMed ID: 29544719
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
